Therapy Name | BKT140 + Nelarabine |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BKT140 | TN14003|BL-8040|BL8040 | CXCR4 Inhibitor 14 | BKT140 is a selective CXCR4 antagonist that prevents SDF-1 (CXCL12) binding, which may lead to decreased tumor growth (PMID: 21138752). | |
Nelarabine | Arranon | GW-506U78 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02763384 | Phase II | BKT140 + Nelarabine | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | Recruiting |